The lack of increase in the ABBV price is saying that the overall [HCV] market has decreased significantly.Such a conclusion is inconsistent with ENTA’s 10% increase today. An alternative explanation for ABBV’s weak showing today is that the ESRX deal has scary implications vis-à-vis Humira—and Humira FoBs.